Table 1.

Patients’ characteristics, n = 32

Male/female patients	50%/50%
Median age, years (range)	54 (30.8–71.5)
Preceding alloHSCT 1/2 (n)	26/6
Diagnosis at last alloHSCT	n
AML	26
MDS	4
CMML	1
aCML	1
CR/no CR at last alloHSCT (n)	9/23
Graft	n
MSD	4
MUD	21
Haploidentical family donor	7
MAC/RIC	15/17
Median time from alloHCST to REL, months (range)	5.7 (1.1–67.8)
Type of relapse	n
Molecular relapse (MR)	5
Hematological relapse (HR)	23
Extramedullary relapse (XR) (+HR/MR)	4 (3/1)
1st relapse after 1st alloHSCT	21
2nd relapse after 1st alloHSCT	5
1st relapse after 2nd alloHSCT	4
2nd relapse after 2nd alloHSCT	2
Diagnosis at HMAClax therapy	n
AML	30
MDS	2
ELN classification at HMAClax therapy for AML patients	n
High risk	20
Intermediate risk	6
Low risk	4
Cytogenetics at HMAClax therapy
Complex karyotypes	11 (4 including 17p)
Molecular proven TP53 mutations	4
IDH 1 or 2 mutations	3*
NPM1 mutation	5*
Median blast count in bone marrow	20% (0–90)
Median white blood cell count/μl	4030 (500–220,000)
Median hemoglobin level (g/dl)	10 (6.9–15.4)
Median platelet count/μl	40,000 (1000–339,000)

*One patient had NPM1 mutation in combination with IDH1, TP53, and DNMT3a mutation

alloHSCT allogeneic hematopoietic stem cell transplantation, AML acute myeloid leukemia, MDS myelodysplastic syndrome, CMML chronic myelomonocytic leukemia, aCML atypical chronic myeloid leukemia, CR complete remission, MSD matched sibling donor, MUD matched unrelated donor, MAC myeloablative conditioning, RIC reduced intensity conditioning, REL relapse, MR molecular relapse, HR hematological relapse, XR extramedullary relapse, ELN European LeukemiaNet